Methods to increase patients’ resistance and compliance to statins may increase the potency of dyslipidemia treatment at those posessing the risk of CVD or cardiovascular disease.
The aim here is to analyse the advantages and disadvantages of arbitration to develop statin resistance in the patients threatened by CVD.
Our Data Sources are MEDLINE, EMBASE, PubMed, and the Cochrane Library from December 2013 to May 2019.
Specific systematic reviews (SRs), randomized controlled trials (RCTs) and group studies that addressed arbitration to increase statin resistance were chosen.
One of our investigators abstracted data and assessed study quality, and a second investigator checked abstractions and assessments for accuracy.
The SR found that intensified patient care improved adherence and decreased levels of total serum cholesterol and low-density lipoprotein cholesterol (LDL-C) at 6 months or more of follow-up. Escalated care of patients increased resistance to statin and lowered total serum cholesterol and lipoprotein cholesterol level (LDL-C) after observing the patient for 6 months, as per the SR. In comparison to statin treatment being stopped, the statin dosage reduced the total cholesterol and LDL-C levels. As reported by 2 group studies, less than only 10% of the patients who were initially statin intolerant and had low levels of vitamin D were not able to comply with statin after a year of consuming Vitamin D supplements.
The evidence suggested that a lower dose of statin and escalated patient care seems to be good choices for increasing statin resistance.